Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

tert-Butylphenolic Derivatives from Paenibacillus odorifer-A Case of Bioconversion.

Nguyen TB, Delalande O, Rouaud I, Ferron S, Chaillot L, Pedeux R, Tomasi S.

Molecules. 2018 Aug 5;23(8). pii: E1951. doi: 10.3390/molecules23081951.

2.

Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.

McClurg UL, Nabbi A, Ricordel C, Korolchuk S, McCracken S, Heer R, Wilson L, Butler LM, Irving-Hooper BK, Pedeux R, Robson CN, Riabowol KT, Binda O.

Br J Cancer. 2018 Mar 6;118(5):713-726. doi: 10.1038/bjc.2017.447. Epub 2018 Jan 30.

3.

Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence.

Loisel S, Dulong J, Ménard C, Renoud ML, Meziere N, Isabelle B, Latour M, Bescher N, Pedeux R, Bertheuil N, Flecher E, Sensebé L, Tarte K.

Stem Cells. 2017 May;35(5):1431-1436. doi: 10.1002/stem.2580. Epub 2017 Feb 23.

4.

AJP-Cell Physiology begins a theme series on the control of the proteostasis network in health and diseases.

Chevet E, Pedeux R, Lotersztajn S.

Am J Physiol Cell Physiol. 2016 Aug 1;311(2):C163-5. doi: 10.1152/ajpcell.00130.2016. Epub 2016 May 25. No abstract available.

5.

Role of the tumor microenvironment in regulating apoptosis and cancer progression.

Yaacoub K, Pedeux R, Tarte K, Guillaudeux T.

Cancer Lett. 2016 Aug 10;378(2):150-9. doi: 10.1016/j.canlet.2016.05.012. Epub 2016 May 17. Review.

6.

Reply: Standardized procedure for bone marrow MSCs preparation for clinical use.

Bigot N, Sensebé L, Tarte K, Pedeux R.

Stem Cells. 2016 Jul;34(7):1994-5. doi: 10.1002/stem.2390. Epub 2016 May 17. No abstract available.

7.

A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.

Beauchesne P, Quillien V, Faure G, Bernier V, Noel G, Quetin P, Gorlia T, Carnin C, Pedeux R.

Int J Cancer. 2016 Mar 15;138(6):1538-44. doi: 10.1002/ijc.29898. Epub 2015 Nov 20.

8.

Hypoxia Differentially Modulates the Genomic Stability of Clinical-Grade ADSCs and BM-MSCs in Long-Term Culture.

Bigot N, Mouche A, Preti M, Loisel S, Renoud ML, Le Guével R, Sensebé L, Tarte K, Pedeux R.

Stem Cells. 2015 Dec;33(12):3608-20. doi: 10.1002/stem.2195. Epub 2015 Oct 8.

9.

ING1b negatively regulates HIF1α protein levels in adipose-derived stromal cells by a SUMOylation-dependent mechanism.

Bigot N, Guérillon C, Loisel S, Bertheuil N, Sensebé L, Tarte K, Pedeux R.

Cell Death Dis. 2015 Jan 22;6:e1612. doi: 10.1038/cddis.2014.577.

10.

SUMOylation of the ING1b tumor suppressor regulates gene transcription.

Satpathy S, Guérillon C, Kim TS, Bigot N, Thakur S, Bonni S, Riabowol K, Pedeux R.

Carcinogenesis. 2014 Oct;35(10):2214-23. doi: 10.1093/carcin/bgu126. Epub 2014 Jun 5.

11.

The ING tumor suppressor genes: status in human tumors.

Guérillon C, Bigot N, Pedeux R.

Cancer Lett. 2014 Apr 1;345(1):1-16. doi: 10.1016/j.canlet.2013.11.016. Epub 2013 Dec 11. Review.

PMID:
24333729
12.

ING1 and ING2: multifaceted tumor suppressor genes.

Guérillon C, Larrieu D, Pedeux R.

Cell Mol Life Sci. 2013 Oct;70(20):3753-72. doi: 10.1007/s00018-013-1270-z. Epub 2013 Feb 15. Review.

13.

ING2 controls the G1 to S-phase transition by regulating p21 expression.

Larrieu D, Ythier D, Brambilla C, Pedeux R.

Cell Cycle. 2010 Oct 1;9(19):3984-90. Epub 2010 Oct 1.

PMID:
20890119
14.

Sumoylation of ING2 regulates the transcription mediated by Sin3A.

Ythier D, Larrieu D, Binet R, Binda O, Brambilla C, Gazzeri S, Pedeux R.

Oncogene. 2010 Nov 4;29(44):5946-56. doi: 10.1038/onc.2010.325. Epub 2010 Aug 2.

PMID:
20676127
15.

Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

Beauchesne P, Bernier V, Carnin C, Taillandier L, Djabri M, Martin L, Michel X, Maire JP, Khalil T, Kerr C, Gorlia T, Stupp R, Pedeux R.

Neuro Oncol. 2010 Jun;12(6):595-602. doi: 10.1093/neuonc/noq008. Epub 2010 Feb 11.

16.

Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma.

Ythier D, Brambilla E, Binet R, Nissou D, Vesin A, de Fraipont F, Moro-Sibilot D, Lantuejoul S, Brambilla C, Gazzeri S, Pedeux R.

Lung Cancer. 2010 Aug;69(2):180-6. doi: 10.1016/j.lungcan.2009.11.006. Epub 2009 Dec 4.

PMID:
19962781
17.

WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway.

Binet R, Ythier D, Robles AI, Collado M, Larrieu D, Fonti C, Brambilla E, Brambilla C, Serrano M, Harris CC, Pedeux R.

Cancer Res. 2009 Dec 15;69(24):9183-91. doi: 10.1158/0008-5472.CAN-09-1016.

18.

SharING out the roles in replicatING DNA.

Larrieu D, Pedeux R.

Cell Cycle. 2009 Nov 15;8(22):3623-4. No abstract available.

PMID:
19884798
19.

ING2 controls the progression of DNA replication forks to maintain genome stability.

Larrieu D, Ythier D, Binet R, Brambilla C, Brambilla E, Sengupta S, Pedeux R.

EMBO Rep. 2009 Oct;10(10):1168-74. doi: 10.1038/embor.2009.180. Epub 2009 Sep 4.

20.

Interference with netrin-1 and tumor cell death in non-small cell lung cancer.

Delloye-Bourgeois C, Brambilla E, Coissieux MM, Guenebeaud C, Pedeux R, Firlej V, Cabon F, Brambilla C, Mehlen P, Bernet A.

J Natl Cancer Inst. 2009 Feb 18;101(4):237-47. doi: 10.1093/jnci/djn491. Epub 2009 Feb 10.

PMID:
19211441

Supplemental Content

Loading ...
Support Center